Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.